David Meek­er starts the next chap­ter of his long biotech ca­reer as chair­man of the board

David Meek­er may be leav­ing Sanofi Gen­zyme af­ter a long run at the big Boston op­er­a­tion, but he’s stay­ing in biotech.

Meek­er re­cent­ly an­nounced his re­tire­ment from the Sanofi sub­sidiary, ef­fec­tive in June, and to­day he’s tak­ing the chair­man’s role at Rhythm, a Boston-based start­up that is de­vel­op­ing pep­tide ther­a­pies for rare ge­net­ic con­di­tions.

Meek­er is fol­low­ing a path blazed by for­mer boss Hen­ri Ter­meer, who fol­lowed the $20 bil­lion sale of Gen­zyme with a high-pro­file role seed­ing biotech star­tups and serv­ing on a va­ri­ety of boards in the hot life sci­ences hub.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.